Premium
Hyperfibrinogenemia and metabolic syndrome in type 2 diabetes: a population‐based study
Author(s) -
Bruno Graziella,
CavalloPerin Paolo,
Bargero Giuseppe,
Borra Milena,
D'Errico Nicola,
Macchia Giuseppe,
Pagano Gianfranco
Publication year - 2001
Publication title -
diabetes/metabolism research and reviews
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.307
H-Index - 110
eISSN - 1520-7560
pISSN - 1520-7552
DOI - 10.1002/1520-7560(2000)9999:9999<::aid-dmrr166>3.0.co;2-g
Subject(s) - medicine , metabolic syndrome , fibrinogen , diabetes mellitus , blood pressure , population , endocrinology , dyslipidemia , type 2 diabetes , cohort , gastroenterology , environmental health
Background It has been hypothesized that fibrinogen clusters with several components of the metabolic syndrome, thus increasing its cardiovascular risk. The aims of the present study were to assess in a large population‐based cohort of patients with type 2 diabetes (1) variables associated with fibrinogen and (2) the relationship between hyperfibrinogenemia, a number of components of the metabolic syndrome, and coronary heart disease (CHD). Methods We identified a cross‐sectional, population‐based cohort of 1574 patients with type 2 diabetes using multiple sources of ascertainment. Components of the metabolic syndrome were hypertension (systolic blood pressure ≥160 mmHg and/or diastolic blood pressure ≥95 mmHg and/or treatment with antihypertensive drugs), dyslipidemia (tryglicerides >2.82 mmol/l and/or HDL‐cholesterol <1.03 mmol/l), hyperuricemia (uric acid >416 µmol/l) and increased albumin excretion rate (AER ≥20 µg/min). Results Fibrinogen increases with age, HbA 1c , smoking, hypertension and a number of components of the metabolic syndrome, even after adjustment for confounders. Prevalence of CHD increases linearly across quartiles of fibrinogen (from 26.1 to 40.6%, p =0.046). However, in logistic regression, after adjustment for both confounders and known risk factors for CHD, the role of fibrinogen is no more significant, whereas ORs for HbA 1c between 6.8 and 8.8% and >8.8% vs values <6.8% are, respectively, 1.91 (95% CI 1.36–2.69) and 1.56 (1.07–2.27). Conclusions This population‐based study shows that fibrinogen increases with age, HbA 1c , smoking, hypertension and a number of components of the metabolic syndrome, independent of major confounders. We also found that poor blood glucose control was associated with CHD. Copyright © 2000 John Wiley & Sons, Ltd.